. Author manuscript; available in PMC: 2009 May 1.

Published in final edited form as: J Autoimmun. 2008 Jan 31;30(3):172–179. doi: 10.1016/j.jaut.2007.12.002

Table 1. Complete response rates after donor lymphocyte infusion.

High response rates are seen in relapsed chronic myelogenous leukemia, but results are significantly poorer in other disease states, particularly acute leukemia. Abbreviations: CR, complete response; EBMT, European Group for Blood and Marrow Transplantation. EBMT data taken from Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004 Feb 1;103(3):767-76. North American data taken from Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb;15(2):433-44.

Disease	Complete responses/evaluable patients (% CR)
Disease	EBMT	North America

Chronic myelogenous leukemia
Cytogenetic/molecular relapse	40/50 (80%)	3/3 (100%)
Hematological relapse	88/114 (77%)	25/34 (74%)
Accelerated phase/blast crisis	13/36 (36%)	5/18 (28%)

Acute myeloid leukemia/myelodysplastic syndrome	15/58 (26%)	8/44 (18%)

Acute lymphoblastic leukemia	3/20 (15%)	2/11 (18%)

Multiple myeloma	5/17 (29%)	2/4 (50%)

Non-Hodgkin lymphoma	None evaluated	0/6 (0%)